<?xml version="1.0" encoding="UTF-8"?>
<table xmlns="http://www.w3.org/1999/xhtml">
 <caption class="caption">
  <label class="label">Table 2</label>
  <p class="p" xmlns="">Various anticancer activities of non-curcuminoids.</p>
 </caption>
 <thead class="thead">
  <tr class="tr" xmlns="">
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" class="th">Non-Curcuminoids</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" class="th">Various Anticancer Studies</th>
   <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1" class="th">References</th>
  </tr>
 </thead>
 <tbody class="tbody">
  <tr class="tr" xmlns="">
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Turmerone</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Unlike curcuminoids, turmerone brought apoptosis due to the distortion caused to the mitochondria in the intrinsic pathway with activation in procaspase-3 cleavage</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B33-biomolecules-09-00013" ref-type="bibr" class="xref">33</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="11" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">Ar-turmerone</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone brought apoptosis on various cell lines such as K562, RBL-2H3, L1210, and U937 in time and dose-dependent manner.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B34-biomolecules-09-00013" ref-type="bibr" class="xref">34</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone facilitated curcumin transport through heterogeneous human epithelial colorectal adenocarcinoma (Caco 2) cells and inhibited the efflux of rhodamine-123 and permeability glycoprotein multidrug resistant gene messenger ribonucleic acid (Pgp (MDRI gene) mRna) expression levels.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B35-biomolecules-09-00013" ref-type="bibr" class="xref">35</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone suppressed 12-O-tetradecanoylphorbol-13-acetate (TPA)- induced up-regulation of matrix metalloproteinase -9 (MMP-9) and cyclooxygenase-2 (COX-2) expression by blocking nuclear factor kappa light chain enhancer of activated B cells (NF-kB), Phosphoinositide 3-kinase/ protein kinase B (PI3K/Akt) and extracellular regulated kinase (ERK)1/2 signaling in human breast cancer cells and inhibited TPA induced invasion, migration, and colony formation in human breast cancer cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B36-biomolecules-09-00013" ref-type="bibr" class="xref">36</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone was effective on murine dendritic cells (DCs).</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B37-biomolecules-09-00013" ref-type="bibr" class="xref">37</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone showed inhibitory action against hepatocellular carcinoma cells by apoptosis through intracellular reactive oxygen species (ROS) generation-mediated activation of ERK and c Jun N terminal kinase (JNK) kinases.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B38-biomolecules-09-00013" ref-type="bibr" class="xref">38</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone had cytotoxic effects on Lymphocytic leukemia (L-1210) and myeloid cell line (HL-60) cells with an inhibition rate of 11–12% and apoptosis index 5–6.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B39-biomolecules-09-00013" ref-type="bibr" class="xref">39</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerones enhanced the activities of curcumin in human colon carcinoma (HCT-116), colorectal adenocarcinoma (HT-29) and human umbilical vein endothelial cells (HUVEC) cell lines.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B40-biomolecules-09-00013" ref-type="bibr" class="xref">40</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone, when motif-fused with spiropyrollidone oxindoles increased the potency in lung cancer and leukemia cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B41-biomolecules-09-00013" ref-type="bibr" class="xref">41</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone and its analogs exhibited cytotoxic activities against L1210 cell.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B42-biomolecules-09-00013" ref-type="bibr" class="xref">42</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone exhibited apoptosis through changes in morphological characters.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B43-biomolecules-09-00013" ref-type="bibr" class="xref">43</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Ar-turmerone exhibited apoptosis on human myeloid leukemia HL-60 cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B44-biomolecules-09-00013" ref-type="bibr" class="xref">44</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">Elemene</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Elemene can inhibit the tumor growth of various cells, such as ovarian, laryngeal, non-small cell lung, prostrate, melanoma, leukemia, breast, brain, hepatoma, colorectal adenocarcinoma, glioblastoma, and human cervix epithelioid carcinoma cells</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B45-biomolecules-09-00013" ref-type="bibr" class="xref">45</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Elemene brought apoptosis in HL-60 cell by causing cell cycle arrest between phase transitions from S to G2M phase</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B46-biomolecules-09-00013" ref-type="bibr" class="xref">46</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Elemene can pass through the blood brain barrier due to its small size and lipophilic nature which is helpful in brain carcinomas</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B47-biomolecules-09-00013" ref-type="bibr" class="xref">47</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="25" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">β-elemene</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">The mechanism of action of β-elemene in non-small-cell lung cancer cell (NSCLC) death may be through a mitochondrial release of the cytochrome c-mediated apoptotic pathway.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B48-biomolecules-09-00013" ref-type="bibr" class="xref">48</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene sensitizes the human NSCLC cell lines H460 and A549 to cisplatin via mitochondria mediated intrinsic apoptosis pathway involving B cell lymphoma-2 (Bcl-2) family proteins and IAPs (inhibitor of apoptosis proteins) in a time and dose-dependent manner.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B49-biomolecules-09-00013" ref-type="bibr" class="xref">49</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene exhibited antitumor effect on NSCLC A549 cells and inhibited the activity of the PI3K/Akt/mammalian target of rapamycin (mTOR)/Ribosomal protein S6 kinase beta-1(p70S6K1) signaling pathway, resulting in apoptosis as well as protective autophagy.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B50-biomolecules-09-00013" ref-type="bibr" class="xref">50</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene inhibited ERK and Akt activation and upregulation of Casitas B–lineage lymphoma (c-Cb1 and Cb1-b) expression to initiate apoptosis in lung cancer cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B51-biomolecules-09-00013" ref-type="bibr" class="xref">51</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene has potential to inhibit human lung cancer NSCLC cell growth via ERK1/2- and AMP-activated protein kinase (AMPKa)-mediated inhibition of transcription factor Sp1, followed by reduction in DNA (cytosine-5)-methyltransferase 1(DNMT1) protein expression.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B52-biomolecules-09-00013" ref-type="bibr" class="xref">52</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene in combination with etoposide is beneficial for lung cancer cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B53-biomolecules-09-00013" ref-type="bibr" class="xref">53</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene is a promising therapeutic role in human SGC7901 and MKN45 gastric cancer cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B54-biomolecules-09-00013" ref-type="bibr" class="xref">54</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene and its relation between the expression level of tyrosine-protein kinase Met (c-Met) promoted its anticancer mechanism.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B55-biomolecules-09-00013" ref-type="bibr" class="xref">55</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene can inhibit the proliferation of RCC 786- 0 cells by the inhibition of mitogen activated protein kinase (MAPK)/ERK and PI3K/Akt/mTOR signaling pathway, thus inducing apoptosis and protective autophagy.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B56-biomolecules-09-00013" ref-type="bibr" class="xref">56</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene when treated with taxane over ovarian cell lines A2780/CP70 and its parental cell line A2780 showed promising results.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B57-biomolecules-09-00013" ref-type="bibr" class="xref">57</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene can reverse tumor multi drug resistance (MDR) and enhanced the doxorubicin activity. </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B58-biomolecules-09-00013" ref-type="bibr" class="xref">58</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene showed antiproliferative activity on glioblastoma cells which was supported by phosphorylation of p38 MAPK, cell-cycle arrest in the G0/G1 phase.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B59-biomolecules-09-00013" ref-type="bibr" class="xref">59</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene inhibited the proliferation and survival of the cell lines of glioblastoma multiforme (GBM) when combined with radiotherapy or temozolomide (TMZ) via inhibition of DNA damage repair.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B60-biomolecules-09-00013" ref-type="bibr" class="xref">60</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene arrested glioblastoma cells (C6 and U87) in G0/G1 phase of the cell cycle, as well as brought about inhibition in cell proliferation by regulating the glia mutation factor β/mitogen activated protein kinase 3/6/p38 and extracellular signal-regulated kinase 1/2/B cell lymphoma 2/surviving pathways.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B61-biomolecules-09-00013" ref-type="bibr" class="xref">61</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene enhances susceptibility to cisplatin resistant ovarian cancer cell.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B12-biomolecules-09-00013" ref-type="bibr" class="xref">12</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene exhibited antiproliferative activities, promoted apoptosis, impaired invasiveness in glioblastoma cells, suppressed the growth of animal xenografts.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B62-biomolecules-09-00013" ref-type="bibr" class="xref">62</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene and its derivatives containing a piperazine, a morpholine, a tetrahydropyrrole, a thiophenylethylamine, or a cyclohexamine group exhibited proliferative activity in human cervix epitheloid carcinoma HeLa, gastric carcinoma SGC-7901, and leukemia K562 cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B63-biomolecules-09-00013" ref-type="bibr" class="xref">63</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β elemene monosubstituted amine, ether and rhenium coordinated complex structure was synthesized and characterized. The in vitro anti-proliferative activity of β-elemene monosubstituted amine and Re (CO) 
    <sub class="sub">3</sub>-β-elemene derivatives in human cervix epitheloid carcinoma HeLa cells were promising. 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B64-biomolecules-09-00013" ref-type="bibr" class="xref">64</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene-enhanced inhibitory effect of cisplatin on lung carcinoma cell proliferation, regulated by a check point kinase (CHK) 2-mediated cell division cycle CDC25C/CDC2/cyclin B1 signaling pathway which leads to the blockade of cell cycle progression at G2/M.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B65-biomolecules-09-00013" ref-type="bibr" class="xref">65</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Arsenic trioxide (ATO) combined with the derivative of β-elemene, 
    <italic class="italic">N</italic>-(β-elemene-13-yl) tryptophan methyl ester (ETME) synergistically enhanced the antiproliferative activity and apoptosis in hepatocellular carcinoma (HCC) cells. 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B66-biomolecules-09-00013" ref-type="bibr" class="xref">66</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Novel furoxan-based NO- donating β-elemene hybrids are promising anti-cancer agents.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B67-biomolecules-09-00013" ref-type="bibr" class="xref">67</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Comparison of cytotoxic efficacy of β-elemene and its synthetic analogs [(R or S)–2–((1R,3S,4S)–3–isopropenyl–4–methyl–4–vinylcyclohexyl)–propane–1,2–diol] (Lr-1), [(S)–2–((1R,3S,4S)–3–isopropenyl–4–methyl–4–vinyl–cyclohexyl)–propane–1,2–diol and (R)–2–((1R,3S,4S)–3–isopropenyl–4–methyl–4–vinylcyclohexyl)–propane–1,2–diol] Lr-2) in the brain tumor cell lines A172, CCF-STTG1, and U-87MG proved beneficial.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B68-biomolecules-09-00013" ref-type="bibr" class="xref">68</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">β-elemene was reviewed for its anticancer effects on different cancer cells and apoptosis and cell cycle arrest were found to be the major cause behind its anticancer activities 
    <break class="break"/>β-elemene is influential in altering the functionality and quantity of ABC transporters thereby efficient in doxorubicin resistant breast cancer cells. 
   </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B69-biomolecules-09-00013" ref-type="bibr" class="xref">69</xref>, 
    <xref rid="B70-biomolecules-09-00013" ref-type="bibr" class="xref">70</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">The possible mode of anticancer activity of β-elemene in altering MDR through the inhibition of ABCB1 transporter efflux activity was determined through molecular docking study</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B71-biomolecules-09-00013" ref-type="bibr" class="xref">71</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Docking studies proved that sesquiterpenes have potential biological activities </td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B72-biomolecules-09-00013" ref-type="bibr" class="xref">72</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">δ-elemene</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Increment of p38 MAPK and inducible nitric oxide synthase levels were seen when δ -elemene was treated in NCL-H292 lung cancer cells through activation of the caspase signaling pathway.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B73-biomolecules-09-00013" ref-type="bibr" class="xref">73</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">Furanodiene</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodiene were useful in the treatment of liver diseases.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B74-biomolecules-09-00013" ref-type="bibr" class="xref">74</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodiene was influential on human leukemia HL60 cells, evaluated by DNA fragmentation.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B75-biomolecules-09-00013" ref-type="bibr" class="xref">75</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodiene is an effective agent against uterine cervix cancer, and has a protective effect on the immune function.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B76-biomolecules-09-00013" ref-type="bibr" class="xref">76</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodiene induced cell death in dose-dependent manner when analyzed by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay MTT assay, thus effective against uterine cervical cancer growth.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B77-biomolecules-09-00013" ref-type="bibr" class="xref">77</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Bioavailability of furanodiene in rat’s plasma as analyzed with liquid chromatography/tandem mass spectrometry was about 49.0%.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B78-biomolecules-09-00013" ref-type="bibr" class="xref">78</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodiene suppresses breast cancer cell growth both in vitro and in vivo in a dose-dependent manner inducing cell cycle arrest at the G0/G1 phase.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B79-biomolecules-09-00013" ref-type="bibr" class="xref">79</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodiene increases the inhibition activities and apoptosis nature of tamoxifen, thus facilitating the treatment of breast cancer. It was beneficial against proliferation carried out by vascular endothelial growth factor (VEGF).</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B80-biomolecules-09-00013" ref-type="bibr" class="xref">80</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodiene showed antiproliferative activity on A549, NIH-H1299, and 95-D lung cancer cells and was useful in combination therapy with paclitaxel.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B81-biomolecules-09-00013" ref-type="bibr" class="xref">81</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Growth inhibitory and pro-apoptosis activity of furanodiene was enhanced and affected Tamoxifen (TAM) by inducing cell cycle arrest and cell apoptosis.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B82-biomolecules-09-00013" ref-type="bibr" class="xref">82</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodiene suppresses proliferation and increase the lactate dehydrogenase (LDH) release in a dose-dependent manner by cell cycle arrest at G0/G1 phase and apoptosis in breast cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B83-biomolecules-09-00013" ref-type="bibr" class="xref">83</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Doxorubicin-resistant MCF-7 (MCF-7/DOXR) breast cancer cells, when treated with furanodiene showed an alteration in mitochondrial function as well as adenosine triphosphate (ATP) levels were reduced causing apoptotic cell death.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B84-biomolecules-09-00013" ref-type="bibr" class="xref">84</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">The combinational treatment of furanodiene with doxorubicin in breast cancer cells were found promising.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B85-biomolecules-09-00013" ref-type="bibr" class="xref">85</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">Furanodienone</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodienone inhibited cell cycle proliferation and induced apoptosis in dose-dependent manner by inhibiting estrogen receptor alpha signaling alpha and mRNA expression levels without effecting estrogen receptor (ER) beta.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B86-biomolecules-09-00013" ref-type="bibr" class="xref">86</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodienone also triggered apoptosis on human breast cancer cells through epithelial growth factor pathways.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B87-biomolecules-09-00013" ref-type="bibr" class="xref">87</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Furanodienone induced apoptosis through ROS on colorectal carcinoma cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B88-biomolecules-09-00013" ref-type="bibr" class="xref">88</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">Curcumol</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Curcumol effects cell proliferation by RNA synthesis in a concentration-dependent manner in lung cancer.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B89-biomolecules-09-00013" ref-type="bibr" class="xref">89</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Curcumol bring apoptosis in nasopharyngeal carcinoma CNE-2 cells by down regulation of NF-kb.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B90-biomolecules-09-00013" ref-type="bibr" class="xref">90</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Curcumol induced apoptosis by suppression of PI3K/Nf-kB pathway on hepatic stellate cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B91-biomolecules-09-00013" ref-type="bibr" class="xref">91</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Curcumol exhibited promising anticancer effects when treated on colorectal cancer cells (LOVO).</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B92-biomolecules-09-00013" ref-type="bibr" class="xref">92</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">Cyclocurcumin</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Cyclocurcumin inhibited the proliferation of breast cancer cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B12-biomolecules-09-00013" ref-type="bibr" class="xref">12</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">When combined with curcumin, cyclocurcumin showed nematocidal behavior.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B93-biomolecules-09-00013" ref-type="bibr" class="xref">93</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Trans-to-cis isomerization of cyclocurcumin proved beneficial.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B94-biomolecules-09-00013" ref-type="bibr" class="xref">94</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Through docking study, an insight on the efficiency of cyclocurcumin as therapeutically potential compound for treating various cancers such as ovarian, brain, lymphomas (Hodgkin and non-Hodgkin), lungs, and adrenocortical cancers was provided</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B95-biomolecules-09-00013" ref-type="bibr" class="xref">95</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">Calebin A</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Calebin A inhibited growth and induced apoptosis in drug-resistant human gastric cancer cells reduction in S phase and G2/M phase arrest.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B96-biomolecules-09-00013" ref-type="bibr" class="xref">96</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Calebin A inhibited growth in drug-resistant human colon cancer cells by decreasing the expression of cell cycle regulatory protein and increasing the ROS levels, inducing apoptosis.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B97-biomolecules-09-00013" ref-type="bibr" class="xref">97</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Calebin A has wide scope in multiple myeloma and breast cancer cells by suppression of osteoclastogenesis.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B98-biomolecules-09-00013" ref-type="bibr" class="xref">98</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">Germacrone</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Germacrone inhibited human breast cancer cells by cell cycle arrest and apoptosis with increase in the LDH release and inducing mitochondrial membrane potential depolarization.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B99-biomolecules-09-00013" ref-type="bibr" class="xref">99</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Germacrone inhibits human hepatoma cell lines by protein expression of cyclin B1 decrease and activation of cyclin-dependent kinases inhibitors (CDK)1.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B100-biomolecules-09-00013" ref-type="bibr" class="xref">100</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Germacrone shared relation between the JANUS-activated kinases (JAK2)/ Signal transducer and activator of transcription (STAT) 3 signaling pathway and it induced apoptosis in HepG2 cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B101-biomolecules-09-00013" ref-type="bibr" class="xref">101</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">The combination of germacrone with ADR enhanced the apoptotic effect and resulted in the reduction of anti-apoptotic protein expression levels (Bcl-2) and enhancement of pro-apoptotic protein expression levels (p53 and Bcl 2 associated X protein (Bax) in MCF-7/ADR cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B102-biomolecules-09-00013" ref-type="bibr" class="xref">102</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Germacrone is beneficial in combination therapy with other drugs as it potentiates the anti- tumor activity of methotrexate and 5-fluorouracil on ER α-positive breast cancer cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B103-biomolecules-09-00013" ref-type="bibr" class="xref">103</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">The derivatives of germacrone had inhibitory effects on Bel-7402, HepG2, A549, and HeLa cells.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B104-biomolecules-09-00013" ref-type="bibr" class="xref">104</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Germacrone possess enormous biological activities as proved by molecular docking study</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B105-biomolecules-09-00013" ref-type="bibr" class="xref">105</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Bisacurone</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Bisacurone inhibits adhesion of cancer cells to endothelial cells through down regulation of vascular cell adhesion molecule (Vcam)1 expression.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B106-biomolecules-09-00013" ref-type="bibr" class="xref">106</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1" class="td">Curdione</td>
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Curdione inhibited production of prostaglandin (PG), E2 in lipopolysaccharide (LPS)-stimulated mouse machrophages RAW 264.7 through suppression of enzyme COX-2 mRNA expression in a dose-dependent manner.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B107-biomolecules-09-00013" ref-type="bibr" class="xref">107</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">The three main sesquiterpenes (germacrone, curdione, furanodiene) had proliferative activity on MDA-MB-231 and MCF-7 breast cancer cells, alone or in combination with a fixed-dose-combination.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B108-biomolecules-09-00013" ref-type="bibr" class="xref">108</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Curdione inhibited the proliferation of breast cancer cells in xenograft nude mouse in a dose-dependent manner.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B109-biomolecules-09-00013" ref-type="bibr" class="xref">109</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">Additionally, the pharmacokinetic studies of curdione proved promising.</td>
   <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B110-biomolecules-09-00013" ref-type="bibr" class="xref">110</xref>] 
   </td>
  </tr>
 </tbody>
 <tfoot>
  <p charset="fn" class="fn">
   <p class="p" xmlns="">Abbreviations: ADR, Adriamycin; AMPKa, AMP-activated protein kinase; ATO, arsenic trioxide; ATP, adenosine triphosphate; Bax, Bcl 2 associated X protein; Bcl, B cell lymphoma; CB1, Casitas B–lineage lymphoma; Caco-2, heterogeneous human epithelial colorectal adenocarcinoma cells; CDC, cell division cycle; CHK2, checkpoint kinase; c-Met, tyrosine-protein kinase Met; COX-2, cyclooxygenase-2; DC, dendritic cells; DNMT1, DNA (cytosine-5)-methyltransferase 1; DOXR, doxorubicin; ERK1/2, extracellular regulated kinase; ER, estrogen receptor; ETME, N-(β-elemene-13-yl) tryptophan methyl ester; HCC, hepatocellular carcinoma; GBM, glioblastoma multiforme; HCC, hepatocellular carcinoma; HCT, human colon carcinoma; HL-60, myeloid cell line; HT, colorectal adenocarcinoma; HUVEC, human umbilical vein endothelial cells; JAK, Janus activated kinases; JNK, c Jun N terminal kinase; L1210, lymphocytic leukemia; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; LOVO, colorectal cancer cell; Lr-1, [(R or S)–2–((1R,3S,4S)–3–isopropenyl–4–methyl–4–vinylcyclohexyl)–propane–1,2–diol]; Lr-2- [(S)–2–((1R,3S,4S)–3–isopropenyl–4–methyl–4–vinyl–cyclohexyl)–propane–1,2–diol and (R)–2–((1R,3S,4S)–3–isopropenyl–4–methyl–4–vinylcyclohexyl)–propane–1,2–diol]; MAPK, mitogen activated protein kinase; MDR, multi drug resistance; MMP-9, matrix metalloproteinase-9; mTOR, mammalian target of rapamycin; MTT assay, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay; NCL-H292, mucoepidermoid lung cancer cell; NF-kB, nuclear factor kappa light chain enhancer of activated B cells; NSCLC, non-small cell lung cancer cell; P-gp (MDRI gene) mRNA, permeability glycoprotein multidrug resistant gene messenger ribonucleic acid; PG, prostaglandin; PI3K/Akt, phosphoinositide 3-kinase/ protein kinase B; P70S6K1, ribosomal protein S6 kinase beta-1; ROS, reactive oxygen species; STAT, signal transducer; TAM, tamoxifen; TMZ, Temozolomide; TPA, 12-O-tetradecanoylphorbol -13-acetate; VEGF, vascular endothelial growth factor; Vcam, vascular cell adhesion molecule.</p>
  </p>
 </tfoot>
</table>
